Santos-Díaz, G.; Pérez-Pico, A.M.; Suárez-Santisteban, M.Á.; García-Bernalt, V.; Mayordomo, R.; Dorado, P.
Prevalence of Potential Drug–Drug Interaction Risk among Chronic Kidney Disease Patients in a Spanish Hospital. Pharmaceutics 2020, 12, 713.
https://doi.org/10.3390/pharmaceutics12080713
AMA Style
Santos-Díaz G, Pérez-Pico AM, Suárez-Santisteban MÁ, García-Bernalt V, Mayordomo R, Dorado P.
Prevalence of Potential Drug–Drug Interaction Risk among Chronic Kidney Disease Patients in a Spanish Hospital. Pharmaceutics. 2020; 12(8):713.
https://doi.org/10.3390/pharmaceutics12080713
Chicago/Turabian Style
Santos-Díaz, Gracia, Ana María Pérez-Pico, Miguel Ángel Suárez-Santisteban, Vanesa García-Bernalt, Raquel Mayordomo, and Pedro Dorado.
2020. "Prevalence of Potential Drug–Drug Interaction Risk among Chronic Kidney Disease Patients in a Spanish Hospital" Pharmaceutics 12, no. 8: 713.
https://doi.org/10.3390/pharmaceutics12080713
APA Style
Santos-Díaz, G., Pérez-Pico, A. M., Suárez-Santisteban, M. Á., García-Bernalt, V., Mayordomo, R., & Dorado, P.
(2020). Prevalence of Potential Drug–Drug Interaction Risk among Chronic Kidney Disease Patients in a Spanish Hospital. Pharmaceutics, 12(8), 713.
https://doi.org/10.3390/pharmaceutics12080713